© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Not every medicine on the shelf carries a backstory shaped by years of scientific grit, global collaboration, and a fair share of skepticism. Daclatasvir Dihydrochloride’s development reads like a lesson from the playbook of relentless research, balancing chemical innovation with tough realities faced in clinics. When the race for safer, more effective hepatitis C cures kicked off, interferon therapies left many patients desperate for something gentler and more reliable. Teams worldwide pivoted toward direct-acting antivirals. Daclatasvir, first named BMS-790052 in the exploration days, drew attention for its impact on the NS5A protein, a critical cog in the hepatitis C virus engine. By 2014, data poured in showing marked improvements for those left out by older drugs. Hearing from patients who finally cleared the virus after years of living in limbo cemented the impact. The sense of progress felt real—proof that ideas in a lab notebook can ripple across entire health systems.
Hold a small vial of Daclatasvir Dihydrochloride, and it’s easy to overlook the complexity held in those crystalline grains. This molecule builds on the core structure of Daclatasvir, existing in dihydrochloride salt form to enhance stability and solubility, both critical for making reliable tablets. Its chemical fingerprint—a tangle of aromatic rings, amide linkages, and strategic halogen atoms—reflects heavy thought about how it moves through the body and outsmarts viral machinery. The melting point stays above 280 degrees Celsius, which tells a lot about its thermal resilience. Image the lengths chemists go to filtering these compounds from a soup of similar structures—chromatography steps, careful pH adjustments, and eyes peeled for sneaky byproducts. Analysts run countless NMR and HPLC assays not as formality, but because slight changes could mean the difference between a safe cure and an unpredictable compound. That grit keeps standards high.
It doesn’t matter how many hours researchers spend on paper if the final preparation falls short of purity or quality. Commercial synthesis of Daclatasvir Dihydrochloride leans on stepwise coupling reactions and meticulous purification. Some syntheses tap specific palladium catalysts to stitch together connecting pieces smoothly, cutting down unwanted leftover fragments. Once the compound is ready, manufacturers puzzle over optimal packaging to keep light, air, and moisture from tickling the molecule into instability. Labels carry strict regulatory language, signaling the purity grade, recommended handling, and expiration to avoid lapses in medicine safety. Each batch walks a tightrope: Not just chemistry, but long checklists built to reduce error, protect workers, and reassure caregivers about what they’re prescribing.
One of the starker lessons from decades watching new drugs launch is this: miracles for some can mean new risks for others. Daclatasvir Dihydrochloride didn’t escape this balancing act. Studies catalogued adverse events closely, noting that most people handled the medicine well, while some faced headaches, fatigue, or lab shifts in liver function tests. The real test comes outside controlled clinical trials, in clinics across cities with less support and more existing health problems. Dosing and administration guidelines adapt as new findings emerge. Worker safety draws from lessons in pharmaceutical handling—gloves, masks, clean hoods all matter here, not just for compliance, but to keep those compounding the drug from exposure-related risks. That lived experience on the floor of production sites or pharmacies can’t be glossed over.
The pharmaceutical world loves synonyms almost as much as it loves acronyms. Industry reports use both the generic ‘Daclatasvir Dihydrochloride’ and coded designations from research days, such as BMS-790052, or even trade names pushed during international launches. These layers are more than technical clutter—clarity in naming improves recalls, reduces prescription errors, and keeps research lines untangled. It reminds me how one misplaced label or ambiguous chart entry can mean a ruined trial or, worse, a patient mix-up. Drug databases and regulatory agencies lean on strict synonym policies for good reason.
Daclatasvir Dihydrochloride hasn’t limited itself to its original viral target. Recent years uncovered fresh interest in other disease areas, even in combination therapies for COVID-19 or obscure viral infections. What excites me isn’t just the new clinical trial headlines, but how researchers adjust chemical backbones or tweak dose regimens to try and coax activity against new viral shapes. Some groups study salt forms, prodrugs, or strategic molecular substitutions to overcome resistance—science rarely stops at one major win before charting new directions. Watching the field, I see echoes of earlier decades, cancer researchers stretching beyond their first big breakthrough, always nudging the edge forward.
Nobody wants a wonder medicine with safety corners cut. Daclatasvir Dihydrochloride’s toxicology reports paint a mostly encouraging picture: animal studies flagged high-dose effects involving liver pathways, but standard human regimens sidestep these issues. Scientists pore over long-term surveillance data, aiming to catch rare events or patterns missed in initial trials. Some researchers dig deeper, looking at reproductive and developmental data, knowing that gaps here can spell trouble later on. Nothing replaces candid conversations among doctors, pharmacists, and patients on how new signals match daily experience. We only move forward by listening closely on all fronts.
Pharmaceutical development never hits a finishing line. Daclatasvir Dihydrochloride stands as a milestone, but many rooms remain for improvement. Resistance mutations keep analysts on their toes, encouraging the hunt for layered therapy approaches and chemical upgrades that maintain potency. Research conferences buzz with talk of extending its reach—pairing with next-generation antivirals, refining pediatric dosing, or slashing costs in lower-income regions. Healthcare systems watch new cost-benefit analyses, weighing access, affordability, and patient stories from diverse corners of the world. People keep pressing for open access to pivotal trial data to blunt inequities across borders. In every conversation with frontline clinicians or global policy advocates, it’s clear: success isn’t static. Winning against one virus or in one country won’t quiet the need to adapt, improve, and lift as many as possible with every new chapter in drug development.
Daclatasvir Dihydrochloride changes the outlook for people who face chronic hepatitis C infection. Health workers around the globe view it as a direct-acting antiviral, meaning it targets the virus in ways old treatments could not. It helps block the virus from multiplying. By interrupting the virus replication process, it reduces the amount of virus in the blood, often to levels too low to detect. This kind of progress matters for patients who spent years coping with failed or harsh treatments.
Living with hepatitis C brings more than liver scars. There’s a real risk of cirrhosis or liver cancer if left untreated, not to mention fatigue and stigma. The old drugs, like interferon, often made people feel sicker before they got better, if they did at all. Daclatasvir Dihydrochloride offered a chance for high cure rates, fewer side effects, and no need for injections. Studies, including those published by the World Health Organization, show sustained virological response rates above 90% when using daclatasvir in combination therapies. Patients who once lost hope now talk about returning to work or rebuilding relationships.
Millions depend on affordable and reliable treatments for hepatitis C. Daclatasvir Dihydrochloride matters in both rich and lower-income countries. Patent deals have helped generic versions reach middle and low-income nations. That policy shift opened doors for people who otherwise could not afford treatment. For countries facing high rates of hepatitis C, such as Egypt or Pakistan, access to this drug helps national health systems chip away at huge infection numbers.
Doctors almost always prescribe daclatasvir with another antiviral, such as sofosbuvir. This targeted approach strengthens the virus-fighting power, reduces the chances for resistance, and shortens the length of treatment for most patients. It’s not a one-size-fits-all fix: patients with advanced liver disease, coinfections like HIV, or who take other medications need careful planning to avoid drug interactions. Health providers rely on updated research and guidelines, like those issued by the European Association for the Study of the Liver, to make these decisions.
Access gaps remain. Some health systems lack the budget to subsidize effective drugs like daclatasvir for everyone. Even in places with available medicine, patients might not know about better choices or feel comfortable asking for them. Stigma makes it tough for people to seek help. Public education, community outreach, and clear information about these drugs keep the progress rolling.
Daclatasvir Dihydrochloride changed the conversation about hepatitis C. As someone who’s watched friends struggle with old treatments, seeing the tide turn feels personal. The way forward means pushing for fair pricing, supporting regular testing, and listening to patient stories. By putting people first and championing real access, hope can spread even faster than hepatitis C ever did.
Daclatasvir Dihydrochloride shows up in many doctors’ offices as part of modern hepatitis C treatment. This antiviral drug helps clear the virus from the liver and brings real hope for millions. As with many medicines, the relief it delivers sometimes comes with a few trade-offs. Too often, people head into treatment with only half the story—fixated on the cure, unprepared for day-to-day realities of side effects. From years in patient care, I’ve seen how heads-up conversations about what might happen help folks adjust, complete treatment, and actually get better. That’s why digging into this topic matters for anyone starting this course.
Fatigue leads the list. Many people feel a heavy tiredness that lingers even after a night’s sleep. For some, it’s just a drag in the afternoon. For others, simple walks or errands feel twice as hard. Headaches aren’t rare, either. Sometimes mild, sometimes pounding, these headaches don’t always fade with a glass of water and a nap.
Nausea and upset stomach crop up for a fair share of folks on Daclatasvir Dihydrochloride. Meal times lose their appeal when your gut feels unsettled. These stomach problems rarely knock people out, but they add another layer of frustration. Diarrhea also enters the mix, making bathroom trips more frequent than anyone would like to admit.
Many patients talk about feeling irritable or low. Mood shifts can sneak up, making minor annoyances feel huge. Some chalk this up to the stress of treatment or life disruptions, but the medicine plays a part. My experience tells me that openly tracking these changes with a healthcare team leads to better support and, sometimes, tweaks to “ride it out.”
Not everyone gets joint pain, rash, or changes in appetite, but enough people mention them that they deserve space here. Rash can show up as itchy bumps or patches and can be mild or distracting enough to seek help. Joint aches sometimes echo through the knees and elbows, almost like a stubborn flu. Most people don’t have to stop treatment because of these, but not mentioning them leaves people feeling blindsided.
Rare side effects include anemia or shortness of breath. These don’t pop up often, but regular blood tests pick them up early. A number to call, an attentive nurse, and a good doctor make the difference here. Catching trouble early prevents small problems from turning into treatment-ending crises.
No one wants to learn about side effects the hard way. Over the years, I’ve watched people turn anxiety into action with the right prep work. Good doctors set the stage, outlining what might show up and how to manage daily bumps. Family and friends can read up, too, so support doesn’t drop off at the first sign of trouble.
Simple steps at home—like resting more, keeping track of symptoms, and staying in touch with the clinic—help smooth the tougher days. If headaches come, hydration and breaks from screens ease the pain. Fatigue sometimes calls for half-days or lighter chores. Most pharmacies and clinics now run side effect monitoring lines, so no one gets left stuck with questions or worries.
Daclatasvir Dihydrochloride changes hepatitis C from a lifelong battle to something treatable. Facing side effects honestly, knowing they might come, and preparing with your health team turns dread into just another step to cure. For people dealing with the grind of hepatitis C, that’s more than enough reason to stay informed and ask questions at every visit.
More people face hepatitis C than we like to admit. For years, treatment meant tough choices—long drug cycles, strong side effects, and sometimes, disappointment. Daclatasvir dihydrochloride arrived as a welcome change, fighting the hepatitis C virus (HCV) in ways older medicines couldn’t. But having a promising medication only means something if people take it right. For many, the challenge pops up not in getting a prescription, but in understanding how to follow through at home.
The directions for taking this medication often sound straightforward, yet daily life can throw curveballs. Typically, a doctor will set a single daily dose, taken by mouth. Missing that dose is easier than it sounds when facing shift work, family emergencies, or plain old forgetfulness.
It helps to tie the medication to something you do each morning. Pairing it with breakfast or even setting an alarm on your phone cuts down on missed doses. In my circle, the ones who stick to a schedule by linking pills to a routine, like brushing their teeth or morning coffee, seem to have better success rates. Consistency is what turns treatment from hope into real results.
Daclatasvir doesn’t often act alone. The real power comes when it teams up with other medications, often sofosbuvir. The goal here is clear: kill the virus as fast and as completely as possible. This means following the doctor’s instructions, even on days when symptoms get rough or seem to fade away. These combinations don’t exist to frustrate anyone—they help clear infection and lower the chance the virus comes back strong or develops resistance.
The hepatitis C virus wouldn’t mind if patients got tired and skipped doses. That’s how resistance starts, and that’s how we all lose ground in this medical fight. Real life gets complicated—work gets busy, kids get sick, bills like to pile up—but remembering to swallow that pill every day truly matters.
Food doesn’t stop daclatasvir from doing its job. You can take it with or without meals, but what you wash it down with can matter. Grapefruit and its juice are known to mess with how the liver breaks down lots of medicines, including some hepatitis C drugs, so it makes sense to skip the grapefruit during your treatment months.
Most doctors mention the drinking question. Alcohol puts a strain on a liver already fighting an infection and trying to recover. Quitting or cutting back makes these new medicines work harder in your favor.
No medication is perfect. Some people notice headaches, feeling tired, or stomach troubles. Telling your care team about any new symptoms keeps everyone on the same page and helps spot rare but serious side effects before they get worse.
As much as medicine science has jumped forward, the most important part of beating hepatitis C remains the same: listening, asking questions, and sticking to the path you set with your doctor. Treatment with daclatasvir dihydrochloride gives people a powerful weapon, as long as they use it every single day as intended.
Picture this: You’re holding a prescription for daclatasvir dihydrochloride, a medicine that’s been changing the game for treating hepatitis C. At the same time, your bathroom cabinet is already crowded with other bottles — maybe something for cholesterol, diabetes, or a low dose aspirin just in case. Standing there, the thought crosses your mind: Is it safe to take all these together?
Many of us juggle medicines every day. According to the CDC, about 40% of adults in the United States use at least one prescription drug, and around 12% take five or more. Managing all that can get confusing, and mixing the wrong ones can trigger trouble.
Daclatasvir dihydrochloride targets the hepatitis C virus directly. Doctors usually team it up with other antivirals like sofosbuvir for best results. These drugs chase down the virus in the body and stop it from multiplying. It sounds straightforward, but chemical reactions between medications can throw a wrench into the plan.
Your liver acts as the body’s own chemical plant. Most medicines, including daclatasvir, pass through the liver. Enzymes there break them down, sometimes speeding up or slowing down how long medicines last in your system. Throw certain other meds into the mix, and suddenly those enzymes either flood the system or slow right down. This can make daclatasvir less effective or lead to unexpected side effects.
Some heart medications, especially amiodarone, have earned a spot on the “be careful” list. Mixing this drug with daclatasvir, especially if sofosbuvir is part of the package, can cause a dangerous slow-down in your heart rate. Several antifungal medicines, certain antibiotics, HIV treatments, anticonvulsants, and herbal supplements like St. John’s wort all play a role in bumping up or shrinking down drug levels.
Doctors and pharmacists spend years learning about these combinations for a reason. A medicine that works wonders on its own could turn risky if paired with the wrong thing. Bringing every prescription bottle, over-the-counter remedy, or herbal supplement to your next doctor’s visit can make a real difference. Share any changes in symptoms right away, even if you think they’re too small to matter.
Always read through medication guides and fact sheets. They’re not just paperwork — they clue you in on what to expect. The U.S. FDA and specialty liver disease clinics keep online lists of drug interactions that anyone can access. Sometimes a simple web search saves a lot of pain down the line.
Years working alongside primary care physicians showed me how vital honest conversations are. Good doctors encourage difficult questions, make space for your worries, and adjust course when new problems turn up. Real trust goes miles beyond an internet search or a rushed pharmacy visit.
Living with multiple prescriptions means taking a proactive role in your health. Keeping an updated medication list, chatting regularly with your caregivers, and seeking out trustworthy information puts you in the driver’s seat. Good health starts with straight answers, and sometimes the best question is the simplest: “Is it safe for me to take these together?”
Daclatasvir Dihydrochloride offers a real shot at clearing hepatitis C from the body. For a lot of patients, finally getting rid of this virus feels like a fresh page in the story of their health. It’s not for everyone, though. Some folks, after looking at the facts and listening close to what their bodies tell them, realize that this medicine’s just not a fit. Not because it’s “bad” but because the risks can outweigh the benefits.
Pregnancy throws every medication into question. Daclatasvir Dihydrochloride moves across the placenta and can change what’s going on with a developing baby. Animal studies showed real harm at certain doses, and doctors just don’t have solid evidence to call it safe in humans for mothers-to-be. The same goes for nursing—medicine can pass through breast milk. I’ve seen families grapple with this kind of decision, weighing one risk against another, and it’s always complicated.
Daclatasvir Dihydrochloride doesn’t act alone. The liver and kidneys process it, break it down, and move it out. People with serious liver problems or heavy kidney trouble just can’t count on their organs to handle the workload. That can mean higher levels of the drug building up, and nobody wants to trade viral hepatitis for medication toxicity. Solid evidence from studies points to unpredictable reactions in these groups, and doctors usually steer clear unless there’s no other option.
Mixing medicines is like mixing ingredients in a recipe. Get the mix wrong and you end up with something nobody wants. Daclatasvir interacts with certain drugs—like strong inducers or inhibitors of the enzyme CYP3A4. St. John’s Wort, for example, hammers down the drug’s effectiveness, making it almost pointless. On the other hand, some meds can spike its levels and lead to serious side effects. HIV drugs, certain antibiotics, and seizure medicines can send blood levels of Daclatasvir all over the map.
Allergic reactions might sound rare, but they matter—a lot. Some folks have landed in the hospital with rashes, trouble breathing, or swelling after taking antivirals like Daclatasvir. Anyone with a known allergy to this drug or one of its ingredients gets crossed off the list straight away. Nobody forgets what it feels like to have your throat tighten or skin erupt in hives. That memory weighs more than a thousand studies.
Children and adolescents haven’t had the benefit of big studies looking at safety. Regulatory agencies like the FDA and EMA clearly state that Daclatasvir isn’t approved under 18. Decisions about the elderly get trickier. Researchers report that bodies change with age, and there’s more risk of falls, confusion, or organ issues. Many get a careful review before starting this medicine—there’s just too much at stake to play it by ear.
Caring for hepatitis C means working with a doctor who gets the whole picture. Reading labels and online articles only takes you so far; it’s the deeper conversations with doctors and pharmacists that keep people out of trouble. Honest reporting of other drugs, old medical history, and how life really looks day-to-day allows for smart decisions. The solution sits with teamwork, open communication, and plain truth about what’s right for each person’s body.
| Names | |
| Preferred IUPAC name | methyl (2S)-1-[(2S)-2-[5-[4-[4-[2-(2-tert-butyl-5,6-dihydro-2H-pyrimidin-4-yl)ethyl]piperazin-1-yl]phenyl]1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate dihydrochloride |
| Other names |
Daklinza BMS-790052 Daclatasvir Hydrochloride Daclatasvir HCl |
| Pronunciation | /daːˈklætəsˌvɪr daɪˌhaɪdrəˈklɔːraɪd/ |
| Identifiers | |
| CAS Number | 1009119-65-6 |
| Beilstein Reference | 3843787 |
| ChEBI | CHEBI:90996 |
| ChEMBL | CHEMBL3315521 |
| ChemSpider | 12166122 |
| DrugBank | DB09102 |
| ECHA InfoCard | 03d2beee-dda5-4d93-a317-3e4cbb929311 |
| EC Number | 1092935-14-7 |
| Gmelin Reference | 621089 |
| KEGG | D10168 |
| MeSH | Daclatasvir Dihydrochloride MeSH: Daclatasvir |
| PubChem CID | 71387274 |
| RTECS number | FH2EW4D0OB |
| UNII | RSE4T6F2GS |
| UN number | UN3462 |
| CompTox Dashboard (EPA) | 'DTXSID10859430' |
| Properties | |
| Chemical formula | C40H50Cl2N8O6 |
| Molar mass | 678.6 g/mol |
| Appearance | White to off-white powder |
| Odor | Odorless |
| Density | Density: 1.5 g/cm³ |
| Solubility in water | Soluble in water |
| log P | 1.95 |
| Acidity (pKa) | pKa = 5.20 |
| Basicity (pKb) | 8.4 |
| Magnetic susceptibility (χ) | -83.2×10^-6 cm³/mol |
| Refractive index (nD) | 1.663 |
| Viscosity | Viscous liquid |
| Dipole moment | 6.7 ± 1.0 D |
| Pharmacology | |
| ATC code | J05AX14 |
| Hazards | |
| Main hazards | Suspected of causing cancer. |
| GHS labelling | Not a hazardous substance or mixture according to the Globally Harmonized System (GHS). |
| Pictograms | GHS06, GHS08 |
| Signal word | Warning |
| Hazard statements | Harmful if swallowed. Causes serious eye irritation. May cause respiratory irritation. |
| Precautionary statements | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice/attention. IF ON SKIN: Wash with plenty of water. |
| LD50 (median dose) | > 2000 mg/kg (oral, rat) |
| NIOSH | Not Listed |
| PEL (Permissible) | Not Established |
| REL (Recommended) | 60 mg |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Daclatasvir Ledipasvir Sofosbuvir Velpatasvir Elbasvir |
